Figure 5.

MTL-CEBPA Leads to Differential Effects on Immune Cells in Naive Humanized NSG Mice

As described in Figure 4A, leukocytes from PB and cells from bone marrow (BM) were collected for flow cytometric analysis. Because of mouse-to-mouse variation, we used frequencies of each PB cell subset from individual mice before MTL-CEBPA injection (day 0) as a baseline and then calculated the relative frequency change of each cell subset at day 8. The relative change of each PB cell subset before MTL-CEBPA treatment was defined as 1. (A) Effect of MTL-CEBPA on human CD45⁺ leukocytes in PB. Multiple doses of MTL-CEBPA did not affect the (B) human CD4⁺ T cell subset and the (C) human CD8⁺ T cell subset in PB. MTL-CEBPA treatment increased the (D) human CD14⁺ monocyte subset and (E) human CD16⁺ granulocyte subset in PB. (F) Effect of MTL-CEBPA on human leukocytes in BM. MTL-CEBPA reduced (G) the human CD4⁺ T cell subset, but (H) did not significantly change the human CD8⁺ T cell subset in BM. MTL-CEBPA treatment reduced (I) the human CD14⁺ monocyte subset, and (J) the human CD16⁺ granulocyte subset in BM. Each flow analysis was performed in duplicate. Data are presented as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ns, no significant difference. Analysis by two-tailed Student’s t test.